Pattern Announces Promising In Vivo Antiproliferative Activity Against High-Grade Serous Ovarian Cancer with Two Novel Drug Combinations
REDMOND, WA, June 13, 2023 — Pattern Computer®, Inc. (Pattern), a leading AI-powered technology company dedicated to advancing innovative treatments for cancer, is pleased to announce significant progress in the fight against ovarian cancer. Two novel drug combinations, tested at a leading global contract research organization, have exhibited significant tumor growth inhibition (TGI) in an in vivo model of high-grade serous ovarian cancer. This groundbreaking discovery brings hope to patients and healthcare professionals battling this aggressive form of ovarian cancer.
High-grade serous ovarian cancer is one of the most lethal gynecological malignancies, posing a substantial challenge to effective treatment. Recognizing the urgent need for improved therapeutic options, Pattern embarked on a comprehensive research program aimed at identifying novel drug combinations with potentially synergistic antiproliferative properties against high-grade serous ovarian cancer.
Through meticulous experimentation and preclinical studies, Pattern has successfully identified two drug combinations that demonstrated remarkable efficacy in inhibiting tumor growth in an in vivo model. The results showed a substantial reduction in tumor volume, raising optimism for the development of effective treatment strategies targeting high-grade serous ovarian cancer.
“We are increasingly excited by, and proud of, the PatternBio™ team’s work on the path to improving outcomes in our Project StarBright™`, addressing the top five global cancers. As we add successful testing against high-grade serous ovarian cancer to our drug discovery list, we continue to gain confidence in the Pattern Discovery Engines™ that are behind true Explainable AI. We appear to be rapidly on the way to becoming the most productive drug discovery company in oncology, something every employee and shareholder finds personally rewarding.
“This extends our recently reported history of discovering five new, novel, patentable drugs against the top five cancers, per month, with at least one per month passing third-party tests,” said Mark R. Anderson, Founding Chair and CEO of Pattern Computer.
The success of these drug combinations in preclinical testing marks a crucial milestone in the research and development of innovative therapies for high-grade serous ovarian cancer. Pattern is committed to further advancing this breakthrough and is actively pursuing partnerships with pharmaceutical companies, biotech firms, and academic institutions to expedite the translation of these findings into clinical trials.
The foregoing contains statements about the Pattern Computer’s future that are not statements of historical fact. These statements are “forward looking statements” for purposes of applicable securities laws and are based on current information and/or management’s good faith belief as to future events. The words “believe,” “expect,” “anticipate,” “project,” “should,” “could,” “will,” and similar expressions signify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance. By their nature, forward-looking statements involve inherent risk and uncertainties, which change over time, and actual performance could differ materially from that anticipated by any forward-looking statements. Pattern Computer undertakes no obligation to update or revise any forward-looking statement.
About Pattern Computer
Pattern Computer, Inc., a Seattle-area startup, uses its proprietary Pattern Discovery Engine™ to solve the most important and most intractable problems in business and medicine. Its proprietary mathematical techniques can find complex patterns in very-high-order data that have eluded detection by much larger systems.
While the company is currently applying its computational platform to the challenging field of drug discovery, it is also making pattern discoveries for partners in several other sectors, including additional biomedical research, materials science, aerospace manufacturing, veterinary medicine, air traffic operations, and finance.
CONTACT: Denyse Hudson – 360.298.0658 – denyse@patterncomputer.com
Copyright © 2023 Pattern Computer Inc. All Rights Reserved. Pattern Computer, Inc., Pattern Discovery Engine, ProSpectral, ProjectStarBright and PatternBio are trademarks of Pattern Computer Inc. or its subsidiaries. Other trademarks may be trademarks of their respective owners.